These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24557790)

  • 1. The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis.
    Li H; Wang X; Wang X
    Int J Biol Markers; 2014; 29(3):e224-32. PubMed ID: 24557790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer.
    Li J; Xu D; Huang J; Wang YN; Ma XP; Lin ZY; Gong P
    Int J Biol Markers; 2019 Dec; 34(4):389-397. PubMed ID: 31603383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.
    Tibaldi C; Giovannetti E; Tiseo M; Leon LG; D'Incecco A; Loosekoot N; Bartolotti M; Honeywell R; Cappuzzo F; Ardizzoni A; Peters GJ
    Ann Oncol; 2012 Mar; 23(3):670-677. PubMed ID: 21652582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
    Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
    Ding X; Chen W; Fan H; Zhu B
    Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
    Joerger M; Burgers JA; Baas P; Doodeman VD; Smits PH; Jansen RS; Vainchtein LD; Rosing H; Huitema AD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):25-33. PubMed ID: 21590444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
    Maring JG; Wachters FM; Slijfer M; Maurer JM; Boezen HM; Uges DR; de Vries EG; Groen HJ
    Eur J Clin Pharmacol; 2010 Jun; 66(6):611-7. PubMed ID: 20213492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
    Ludovini V; Floriani I; Pistola L; Minotti V; Meacci M; Chiari R; Garavaglia D; Tofanetti FR; Flacco A; Siggillino A; Baldelli E; Tonato M; Crinò L
    J Thorac Oncol; 2011 Dec; 6(12):2018-26. PubMed ID: 22052224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
    Shord SS; Patel SR
    J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
    Tibaldi C; Camerini A; Tiseo M; Mazzoni F; Barbieri F; Vittimberga I; Brighenti M; Boni L; Baldini E; Gilli A; Honeywell R; Chartoire M; Peters GJ; Giovannetti E;
    Br J Cancer; 2018 Nov; 119(11):1326-1331. PubMed ID: 30405211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
    Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
    Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
    Raynal C; Ciccolini J; Mercier C; Boyer JC; Polge A; Lallemant B; Mouzat K; Lumbroso S; Brouillet JP; Evrard A
    Ther Drug Monit; 2010 Feb; 32(1):53-60. PubMed ID: 20010457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
    Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
    Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients.
    Hu L; Mao X; Gao C; Xu Y; Li C; Wang T; Lv D
    Neoplasma; 2021 May; 68(3):638-644. PubMed ID: 33724861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
    Yonemori K; Ueno H; Okusaka T; Yamamoto N; Ikeda M; Saijo N; Yoshida T; Ishii H; Furuse J; Sugiyama E; Kim SR; Kikura-Hanajiri R; Hasegawa R; Saito Y; Ozawa S; Kaniwa N; Sawada J
    Clin Cancer Res; 2005 Apr; 11(7):2620-4. PubMed ID: 15814642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
    Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
    Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
    Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
    PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of association of genetic variations of deoxycytidine kinase with toxicity or survival of non-small-cell lung cancer patients treated with gemcitabine plus cisplatin.
    Ryu JS; Kim HJ; Shin ES; Nam HS; Cho JH; Lee JE
    Oncol Res; 2012; 20(1):25-30. PubMed ID: 23035362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
    Metharom E; Galettis P; Manners S; Jelinek M; Liauw W; de Souza PL; Hoskins JM; Links M
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):65-74. PubMed ID: 21332653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
    Farrell JJ; Bae K; Wong J; Guha C; Dicker AP; Elsaleh H
    Pharmacogenomics J; 2012 Oct; 12(5):395-403. PubMed ID: 21625252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.